Emergence of hepatitis C virus NS5A L31V plus Y93H variant upon treatment failure of daclatasvir and asunaprevir is relatively resistant to ledipasvir and NS5B polymerase nucleotide inhibitor GS-558093 in human hepatocyte chimeric mice

Journal of Gastroenterology

Volumn 50, Issue 11, 2015, Pages 1145-1151

  Kai, Yugo ^a   Hikita, Hayato ^a   Tatsumi, Tomohide ^a   Nakabori, Tasuku ^a   Saito, Yoshinobu ^a   Morishita, Naoki ^a   Tanaka, Satoshi ^a   Nawa, Takatoshi ^a   Oze, Tsugiko ^a   Sakamori, Ryotaro ^a   Yakushijin, Takayuki ^a   Hiramatsu, Naoki ^a   Suemizu, Hiroshi ^b   Takehara, Tetsuo ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b CENTRAL INSTITUTE FOR EXPERIMENTAL ANIMALS   (Japan)

Author keywords

Asunaprevir daclatasvir; Ledipasvir sofosbuvir; Resistance associated variants (RAVs)

Indexed keywords

ASUNAPREVIR; DACLATASVIR; ENZYME INHIBITOR; GS 558093; LEDIPASVIR; NONSTRUCTURAL PROTEIN 5A; NONSTRUCTURAL PROTEIN 5B; SOFOSBUVIR; TELAPREVIR; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS RNA; Y93H PROTEIN; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; BMS-790052; DRUG COMBINATION; FLUORENE DERIVATIVE; IMIDAZOLE DERIVATIVE; ISOQUINOLINE DERIVATIVE; SULFONAMIDE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL RESISTANCE; ARTICLE; CASE REPORT; CONTROLLED STUDY; DRUG TREATMENT FAILURE; FEMALE; GENETIC VARIABILITY; HEPATITIS; HEPATITIS C; HEPATITIS C RAPID TEST; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; HUMAN CELL; INOCULATION; MALE; MIDDLE AGED; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRAL GENETICS; WILD TYPE; ANIMAL; DRUG COMBINATION; DRUG EFFECTS; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HEPATITIS, VIRAL, ANIMAL; HISTOCOMPATIBILITY; LIVER CELL; MULTIDRUG RESISTANCE; TREATMENT FAILURE; VIROLOGY;

ANIMALS; ANTIVIRAL AGENTS; BENZIMIDAZOLES; DRUG COMBINATIONS; DRUG RESISTANCE, MULTIPLE, VIRAL; FEMALE; FLUORENES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HEPATITIS, VIRAL, ANIMAL; HEPATOCYTES; HUMANS; IMIDAZOLES; ISOQUINOLINES; MALE; MIDDLE AGED; SOFOSBUVIR; SULFONAMIDES; TRANSPLANTATION CHIMERA; TREATMENT FAILURE;

EID: 84946488527     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-015-1108-6     Document Type: Article

References (20)

1. Aghemo A, De Francesco R. New horizons in hepatitis C antiviral therapy with direct-acting antivirals. Hepatology. 2013;58:428–38.
2. Poole RM. Daclatasvir + asunaprevir: first global approval. Drugs. 2014;74:1559–71.
3. Lok AS, Gardiner DF, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med. 2012;366:216–24.
4. Kumada H, Suzuki Y, Ikeda K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology. 2014;59:2083–91.
5. Manns M, Pol S, Jacobson IM, et al. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet. 2014;384:1597–605.
6. Karino Y, Toyota J, Ikeda K, et al. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir. J Hepatol. 2013;58:646–54.
7. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370:1889–98.
8. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370:1483–93.
9. Mizokami M, Yokosuka O, Takehara T, et al. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. Lancet Infect Dis. 2015;15(6):645–53.
10. Hasegawa M, Kawai K, Mitsui T, et al. The reconstituted ‘humanized liver’ in TK-NOG mice is mature and functional. Biochem Biophys Res Commun. 2011;405:405–10.
11. Lam AM, Edwards TE, Mosley RT, et al. Molecular and structural basis for the roles of hepatitis C virus polymerase NS5B amino acids 15, 223, and 321 in viral replication and drug resistance. Antimicrob Agents Chemother. 2014;58:6861–9.
12. Wong KA, Worth A, Martin R, et al. Characterization of Hepatitis C virus resistance from a multiple-dose clinical trial of the novel NS5A inhibitor GS-5885. Antimicrob Agents Chemother. 2013;57:6333–40.
13. Friborg J, Zhou N, Han Z, et al. In vitro assessment of re-treatment options for patients with hepatitis C virus genotype 1b infection resistant to daclatasvir plus asunaprevir. Infect Dis Ther. 2014;4(1):137–44.
14. Halfon P, Locarnini S. Hepatitis C virus resistance to protease inhibitors. J Hepatol. 2011;55:192–206.
15. Takehara T. Simeprevir for the treatment of chronic hepatitis C genotype 1 infection. Expert Rev Anti Infect Ther. 2014;12:909–17.
16. Gane EJ, Stedman CA, Hyland RH, et al. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection. Gastroenterology. 2014;146:736–43 (e731).
17. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368:1878–87.
18. Fridell RA, Wang C, Sun JH, et al. Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations. Hepatology. 2011;54:1924–35.
19. Lam AM, Espiritu C, Bansal S, et al. Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob Agents Chemother. 2012;56:3359–68.
20. Svarovskaia ES, Dvory-Sobol H, Parkin N, et al. Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials. Clin Infect Dis. 2014;59:1666–74.